Back
 OJCD  Vol.3 No.4 , December 2013
Public health aspects of visceral leishmaniasis in Montenegro
Abstract: Leishmaniasis belongs to the parasitic communicable zoo noses, caused by members of Leishmania species. The infected phlebotomies sand fly carries the parasites, which cause the different forms of disease. Retrospective/prospective review of records for documented cases of visceral leishmaniasis (VL) in period from 1992 to 2012 in Montenegro shows 83 diagnostic cases, and 1 (1.20%) case with dermal leichmaniasis. with 3 (3.61%) deaths cases. Analyses of age show: 36 (43.37%) children and 47 (56.63%) adults. Examinations are based on epidemiological, clinical, hematological, patohystological and serological investigations. Infection can be sub-clinically or clinically manifested with acute, sub-acute, and chronic type. Incubation in clinically manifested infections ranges from several weeks to several months. In our study, the prevalence of general infective syndrome is registered in all of 83 manifested cases (100%). Enlarged spleen in 79 (95.18%) cases, enlarged liver in 37 (44.57%) cases, anemia in 49 (59.04%) cases, pancytopenia in 32 (38.55%) cases, and increased activity of serum aminotransferases in 37 (44.57%) cases. The diagnosis was confirmed by an analysis of bone marrow biopsy material by direct microscopy of serial sections colored by Romanowski and Giemsa s staining, and by immune-biochemical methods. Serological diagnostic is confirmed by using agglutination test. In Montenegro (in humans and dogs) two types of leishmania (L) (L. donovani, L. infantum were presented). As to therapy treatment, the common treating is with antimony drugs: glucantime is relatively satisfactory for a long time. During 2008 there were registered cases not responding to the therapy and those were manifested with relapses after therapy. In the first line of therapy, we used meglumine antimony (Glucantime) in 78 (93.97%) patients. Resistence developed in 7 (8.97%) during treatment, and relapse occurred in 5 (6.41%) patients. It was 1 (1.20%) patient treated with Miltefosine the one who had a relapse, and with Amphotericin B (Ambisome) 4 (4.82%) patients.
Cite this paper: Andric, B. , Terzic, D. , Dupanovic, B. and Andric, A. (2013) Public health aspects of visceral leishmaniasis in Montenegro. Open Journal of Clinical Diagnostics, 3, 195-201. doi: 10.4236/ojcd.2013.34035.
References

[1]   Freitas-Junior, L.H., Chatelain, E., Kim, H.A. and Siquera-Neto, J.L. (2012) Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? International Journal for Parasitology: Drugs and Drug Resistance, 2, 11-19.

[2]   Desjux, P. (1992) Human leishmaniasis: Epidemiology and Public Health aspects. World Health Statistics Quarterly, 45, 267-275.

[3]   Jeronimo, S.M.B., De Queiroz Sousa, A. and Pearson, R.D. (2000) Leishmaniasis. In: Guerrant, R.L., Ed., Tropical Infectious Diseases, 1, 1095-1107.

[4]   Gugushvili, G., Sekhniashvill, E., Lomtadze, Z., Zerekidze, L. and Molashvili, L. (2001) About changes in population of transmissible disease vectors. The collection of works of Research Institute of Medical Parasitology and Tropical Medicine, honored to 75-th Year of its Foundation (December 1999), XXXIII, 29-34.

[5]   Rassi, Y., Firousi, R. and Javadian, E. (2000) Position of visceral leishmaniasis vectors in the Kalebar focus, East Azarbaijan Province. Moderres, 3, 9-14.

[6]   Alvar, J., et al. (2008) The relationship between leishmaniasis and AIDS—The second 10 years. Clinical Micro- biology Reviews, 21, 334-359. http://dx.doi.org/10.1128/CMR.00061-07

[7]   Rosenthal, E., Marty, P. and Poiyot-Martin, I. (1995) Visceral leishmaniasis and HIV-1 co-infection in southern France. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 159-162. http://dx.doi.org/10.1016/0035-9203(95)90476-X

[8]   Ivovic, V., Depaquit, J., Leger, N., Urrano, A. and Papadopulos, B. (2004) Sandflies (Diphtera, Psyhodidae) in the Bar area of Montenegro (Yugoslavia). 2. Presence of promastigotes in Phlebotomus neglecticus and first record of P. kandelakii. Annals of Tropical Medicine and Parasitology, 98, 425-427. http://dx.doi.org/10.1179/000349804225003352

[9]   Ivovic, V., Chaniotis, V., Vujanic, M., Bobic, B., Nikolic, A., Klun, I., Zivkovic, T. and Djurkovic-Djakovic, O. (2010) Life tables and reproductive parameters of phlebotomus neglecticus tonnor, 1921 (Diphtera, Psychodidae) under laboratory condidions. Archives of Biological Science.

[10]   Andric, B. (2002) Clinical features and diagnostics in associated transmisive (Ixodiae) zoonoses. Doctoral dissertation, Medical Faculty University in Novi Sad.

[11]   Andric, B., Pajovic, B., et al. (2010) Travel and tropical medicine. Medical School, University of Montenegro, Podgorica, Montenegro.

[12]   Oshaghi, M.A., Ravastan, N.M., Javadian, E.A., Mohebali, M., Hajjaran, H., et al. (2009) Vector incrimination of sand flies in the most important visceral leishmaniasis focus in Iran. American Journal of Tropical Medicine and Hygiene, 81, 572-577. http://dx.doi.org/10.4269/ajtmh.2009.08-0469

[13]   Division of Communicable Disease Prevention and Control, Commuunicable Disease Program, HPC/HCT, PAHO (1994) Leichmaniasis in the Americas. Epidemiological Bulletin, 15, 8-11.

[14]   Jeronimo, S.M.B., De Queiros Sousa, A. and Pearson, R.D. (2000) Leichmaniasis. Tropical Infectious Diseases, 94, 1095-1107.

[15]   Maltezou, H.C., Siafas, C. and Mavricou, M. (2000) Visceral leishmaniasis during childrod in Southem Grece. Clinical Infectious Diseases, 31, 1139-1143. http://dx.doi.org/10.1086/317455

[16]   Ready, P.D. and Redy, P.D. (2010) Leishmaniasis emergence in Europe. Eurosurveillance, 15, 19505.

[17]   Evans, T.G. and Parson, R.D. (1988) Clinical and immunological responses following accidental inoculation of Leishmania donovani. Transactions of the Royal Society of Tropical Medicine and Hygiene, 82, 854-856. http://dx.doi.org/10.1016/0035-9203(88)90016-8

[18]   Mylero, V., Searle, S. and Blackwell, J.M. (2002) Solute carrier ll a l/Slcl l a l formely Nrramp l/regulates metabolism and release of iron acquired by phagocytic, but not transferin-receptor/mediated, iron uptake. Biochemical Journal, 363, 89-94. http://dx.doi.org/10.1042/0264-6021:3630089

[19]   Murrey, H.W., Berman, J., Davies, R.C. and Saravia, N.G. (2005) Advances in leishmaniasis. Lancet, 366, 1561-1577. http://dx.doi.org/10.1016/S0140-6736(05)67629-5

[20]   Guerin, P.J., Olliaro, P., Sundar, S., et al. (2002) Visceral leishmaniasis current status of control, diagnosis, and treatment, and proposed research and development agenda. Lancet Infectious Diseases, 2, 494-501. http://dx.doi.org/10.1016/S1473-3099(02)00347-X

[21]   Garcia, L., Kindt, A., Bermudez, H., Lianos-Cuentas, A. and De Doncker, S. (2004) Culture independent species typing of neotropical Leishmania for clinical validation of a PCR based assay targeting heat shock protein 70 genes. Journal of Clinical Microbiology, 42, 2294-2297. http://dx.doi.org/10.1128/JCM.42.5.2294-2297.2004

[22]   Tallada, N., Raventos, A. and Martinez, S. (1993) Leishmania lymphadenitis diagnosed by fine-needle aspiration biopsy. Diagnostic Cytopathology, 9, 673-676. http://dx.doi.org/10.1002/dc.2840090614

[23]   Bittenecourt, A.L. and Barral, A. (1991) Evaluation of the histopathological classifications of American cutaneous and mucocutaneous leishmaniasis. Mem. Instituto Oswaldo Cruz, 86, 51-56. http://dx.doi.org/10.1590/S0074-02761991000100009

[24]   Alvar, J., Croft, S. and Olliaro, P. (2006) Chemotherapy in the treatment and control of leichmaniasis. Advances in Parasitology, 61, 224-261. http://dx.doi.org/10.1016/S0065-308X(05)61006-8

[25]   Nishi, G.S. (2011) Visceral leishmaniasis, experimental models for drug discovery. Indian Journal of Medical Research, 133, 27-36.

[26]   Frezard, F., Demicheli, C. and Ribeiro, R.R. (2009) Pentavalent antimonials—New perspectives for old drugs. Molecules, 14, 2317-2336. http://dx.doi.org/10.3390/molecules14072317

[27]   Herwaldt, B.L. and Berman, J.D. (1992) Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. American Journal of Tropical Medicine and Hygiene, 46, 296-306.

[28]   Peters, B.S., Fish, D., Golden, R., Evans, D.A., Bryceson, A.D. and Pinching, A.J. (1990) Visceral leishmaniasis in HIV infection and AIDS: Clinical features and response to therapy. Quarterly Journal of Medicine, 77, 1101-1111. http://dx.doi.org/10.1093/qjmed/77.2.1101

[29]   Russel, D.G. and Wilheim, H. (1986) The involvement of the major surface glycoprotein (gp63) of leishmania promastigotes in attachment to macrophages. Journal of Immunology, 136, 2613-2620.

[30]   Etges, R., Bouvier, J. and Bordier, C. (1986) The major surface protein of leishmania promastigotes is a protease. Journal of Biological Chemistry, 261, 9098-9101.

[31]   Mc Connville, M.J., Bacic, A. and Mitchell, G.F. (1987) Lipophosphoglycan of leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositid lipid anchor. Proceedings of the National Academy of Sciences of the United States of America, 84, 8941-8945. http://dx.doi.org/10.1073/pnas.84.24.8941

[32]   King, D.L., Chang, Y.-D. and Turco, S.J. (1987) Cell surface lipophosphoglycan of leishmania donovani. Molecular and Biochemical Parasitology, 24, 47-53. http://dx.doi.org/10.1016/0166-6851(87)90114-9

[33]   Sypek, J.P. and Wyler, D.J. (1991) Antileishmanial defense in macrophages triggered by Tumor Necrosis Factor expended on CD4+T lymphocyte plasma membrane. Journal of Experimental Medicine, 174, 755-759. http://dx.doi.org/10.1084/jem.174.4.755

[34]   Birkland, T.P., Sypek, J.P. and Wyler, D.J. (1992) Soluble TNF and membrane TNF expressed on CD4+T lymphocytes differ in their ability to activate macrophage antileishmania defence. Journal of Leukocyte Biology, 51, 296-299.

[35]   Mulero, V., Searle, S. and Blackwell, J.M. (2002) Solute carier Il a L/Slcl I a I formely Nrramp l/regulates metabolism and release of iron uptake. Biochemical Journal, 363, 89-84. http://dx.doi.org/10.1042/0264-6021:3630089

[36]   Manson-Bahr, P.E.C. (1989) East African kala azar with special reference to the pathology, prophilaxis and treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene, 53, 123-127. http://dx.doi.org/10.1016/0035-9203(59)90060-4

[37]   Badaro, R., Jones, T.C. and Lorenco, R. (1986) A prospective study of visceral leishmaniasis in an endemic area of Brasil. Journal of Infectious Diseases, 154, 639-649. http://dx.doi.org/10.1093/infdis/154.4.639

[38]   Evens, T.G., Teixeria, M.J. and Mc Auliffe, I.T. (1992) Epidemiology of visceral leishmaniasis in north-east Brasil. Journal of Infectious Diseases, 166, 124-132.

[39]   Russo, D.M., Barral-Netto, M., Barral, A. and Reed, S.G. (1993) Human T-cell responses in leishmania infections. Progress in Clinical Parasitology, 3, 119-144. http://dx.doi.org/10.1007/978-1-4612-2732-8_5

[40]   Reiner, N.E., Ng, W., Wilson, C.B., et al. (1990) Modulation of in vitro monocyte cytokine responses to leishmania donovani. Interferon-gama prevent parasite induced inhibition of Il-1 production and primes monocytes to respond to leishmania by producting both TNF-alpha and Il-1 production and primes monocytes to respond to leushmania by producting both TNF-alpha and Il-1. Journal of Clinical Investigation, 85, 1914-1924. http://dx.doi.org/10.1172/JCI114654

[41]   Alvar, J., et al. (2008) The relationship between leishmaniasis and AIDS—The second 10 years. Clinical Microbiology Reviews, 21, 334-359. http://dx.doi.org/10.1128/CMR.00061-07

 
 
Top